Share-Based Payments - SOP 2007 (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 23, 2017 shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares
Share-Based Payments
Share-based compensation expense | $		$ 5,732	$ 2,545	$ 1,351
SOP 2007
Share-Based Payments
Share-based compensation expense | $		$ 40	$ 95	$ 78
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share) | $ / shares		$ 0.73	$ 0.73	$ 0.73
Exercised (in dollars per share) | $ / shares		0.73	0.73	0.73
Forfeited (in dollars per share) | $ / shares		0.73	0.73
Outstanding balance at end of year (in dollars per share) | $ / shares		$ 0.00	0.73	0.73
Vested and exercisable balance at end of year (in dollars per share) | $ / shares			$ 0.73	$ 0.73
Options
Outstanding at beginning of year (in shares)		109,960	234,760	241,330
Exercised (in shares)		(108,440)	(124,540)	(6,570)
Forfeited (in shares)		(1,520)	(260)
Outstanding at end of year (in shares)		0	109,960	234,760
Vested and exercisable at end of year (in shares)			107,900	229,270
Additional disclosures
Total intrinsic value of options exercised | $		$ 899	$ 860	$ 119
Redomiciliation Transaction | Nabriva Therapeutics plc ("Nabriva Ireland") | Ordinary Shares | SOP 2007
Share-Based Payments
Number of shares to be awarded for each option when exercised	10
Redomiciliation Transaction | Nabriva Therapeutics AG ("Nabriva Austria") | Common Stock | SOP 2007
Share-Based Payments
Number of shares to be awarded for each option when exercised	1
Redomiciliation Transaction | Nabriva Therapeutics AG ("Nabriva Austria") | Ordinary Shares
Additional disclosures
Conversion ratio of common stock to ordinary shares	0.10